Blurbs

SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

SVB Securities analyst Daina Graybosch maintained a Hold rating on Nektar Therapeutics (NKTRResearch Report) on November 7 and set a price target of $5.00. The company’s shares closed yesterday at $3.58.

Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Nektar Therapeutics, and Affimed. According to TipRanks, Graybosch has an average return of -19.2% and a 30.36% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target, implying a 46.09% upside from current levels. In a report released on November 3, Mizuho Securities also maintained a Hold rating on the stock with a $6.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Nektar Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $23.63 million and a GAAP net loss of $59.05 million. In comparison, last year the company earned a revenue of $24.92 million and had a GAAP net loss of $129.71 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Read More on NKTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More